Skip to main content Accessibility help
  • Print publication year: 2015
  • Online publication date: April 2015

Chapter 13 - Pharmacology of neuromuscular blocking agents and their reversal in trauma patients

from Section 2 - Techniques for monitoring, imaging, and pain relief

Related content

Powered by UNSILO


1. Edmark L, Kostova-Aherdan K, Enlund M, Hedenstierna G. Optimal oxygen concentration during induction of general anesthesia. Anesthesiology 2003; 98: 28–33.
2. Brimacombe JR, Berry AM. Cricoid pressure. Can J Anaesth 1997; 44: 414–25.
3. Warner MA, Warner ME, Weber JG. Clinical significance of pulmonary aspiration during the perioperative period. Anesthesiology 1993; 78: 56–62.
4. Kovacs G, Law JA, Ross J, et al. Acute airway management in the emergency department by non-anesthesiologists. Can J Anaesth 2004; 51: 174–80.
5. Krejcie TC, Avram MJ. What determines anesthetic induction dose? It’s the front-end kinetics, doctor! Anesth Analg 1999; 89: 541–4.
6. Shafer SL. Shock values. Anesthesiology 2004; 101: 567–8.
7. Kuipers JA, Boer F, Olofsen E, Bovill JG, Burm AG. Recirculatory pharmacokinetics and pharmacodynamics of rocuronium in patients: The influence of cardiac output. Anesthesiology 2001; 94: 47–55.
8. Martyn JA, Richtsfeld M. Succinylcholine-induced hyperkalemia in acquired pathologic states: Etiologic factors and molecular mechanisms. Anesthesiology 2006; 104: 158–69.
9. Gronert GA. Cardiac arrest after succinylcholine: mortality greater with rhabdomyolysis than receptor upregulation. Anesthesiology 2001; 94: 523–9.
10. Davis L, Britten JJ, Morgan M. Cholinesterase: its significance in anaesthetic practice. Anaesthesia 1997; 52: 244–60.
11. Donati F. Neuromuscular blocking drugs for the new millennium: current practice, future trends–comparative pharmacology of neuromuscular blocking drugs. Anesth Analg 2000; 90: S2–6.
12. Smith CE, Donati F, Bevan DR. Dose–response curves for succinylcholine: Single versus cumulative techniques. Anesthesiology 1988; 69: 338–42.
13. Smith CE, Donati F, Bevan DR. Potency of succinylcholine at the diaphragm and at the adductor pollicis muscle. Anesth Analg 1988; 67: 625–30.
14. Naguib M, Samarkandi A, Riad W, Alharby SW. Optimal dose of succinylcholine revisited. Anesthesiology 2003; 99: 1045–9.
15. Naguib M, Samarkandi AH, El Din ME, et al. The dose of succinylcholine required for excellent endotracheal intubating conditions. Anesth Analg 2006; 102: 151–5.
16. Naguib M, Samarkandi AH, Abdullah K, Riad W, Alharby SW. Succinylcholine dosage and apnea-induced hemoglobin desaturation in patients. Anesthesiology 2005; 102: 35–40.
17. Hayes AH, Breslin DS, Mirakhur RK, Reid JE, O’Hare RA. Frequency of haemoglobin desaturation with the use of succinylcholine during rapid sequence induction of anaesthesia. Acta Anaesthesiol Scand 2001; 45: 746–9.
18. Heier T, Feiner JR, Lin J, Brown R, Caldwell JE. Hemoglobin desaturation after succinylcholine-induced apnea: a study of the recovery of spontaneous ventilation in healthy volunteers. Anesthesiology 2001; 94: 754–9.
19. Lacroix M, Donati F, Varin F. Pharmacokinetics of mivacurium isomers and their metabolites in healthy volunteers after intravenous bolus administration. Anesthesiology 1997; 86: 322–30.
20. Jooste EH, Sharma A, Zhang Y, Emala CW. Rapacuronium augments acetylcholine-induced bronchoconstriction via positive allosteric interactions at the M3 muscarinic receptor. Anesthesiology 2005; 103: 1195–203.
21. Martineau RJ, St Jean B, Kitts JB, et al. Cumulation and reversal with prolonged infusions of atracurium and vecuronium. Can J Anaesth 1992; 39: 670–6.
22. Fodale V, Santamaria LB. Laudanosine, an atracurium and cisatracurium metabolite. Eur J Anaesthesiol 2002; 19: 466–73.
23. Miller RD, Rupp SM, Fisher DM, et al. Clinical pharmacology of vecuronium and atracurium. Anesthesiology 1984; 61: 444–53.
24. Kisor DF, Schmith VD. Clinical pharmacokinetics of cisatracurium besilate. Clin Pharmacokinet 1999; 36: 27–40.
25. Bryson HM, Faulds D. Cisatracurium besilate. A review of its pharmacology and clinical potential in anaesthetic practice. Drugs 1997; 53: 848–66.
26. Miller DR, Wherrett C, Hull K, Watson J, Legault S. Cumulation characteristics of cisatracurium and rocuronium during continuous infusion. Can J Anaesth 2000; 47: 943–9.
27. Khuenl-Brady KS, Sparr H. Clinical pharmacokinetics of rocuronium bromide. Clin Pharmacokinet 1996; 31: 174–83.
28. Andrews JI, Kumar N, van den Brom RH, et al. A large simple randomized trial of rocuronium versus succinylcholine in rapid-sequence induction of anaesthesia along with propofol. Acta Anaesthesiol Scand 1999; 43: 4–8.
29. Naguib M, Kopman AF, Ensor JE. Neuromuscular monitoring and postoperative residual curarisation: a meta-analysis. Br J Anaesth 2007; 98: 302–16
30. Murphy GS, Brull SJ. Residual neuromuscular block: lessons unlearned. Part I: definitions, incidence, and adverse physiological effects of residual neuromuscular block. Anesth Analg 2010; 111: 120–8.
31. Murphy GS, Szokol JW, Marymont JH, et al. Recovery of neuromuscular function after cardiac surgery: Pancuronium versus rocuronium. Anesth Analg 2003; 96: 1301–7.
32. Kirov K, Motamed C, Dhonneur G. Differential sensitivity of abdominal muscles and the diaphragm to mivacurium: An electromyographic study. Anesthesiology 2001; 95: 1323–8.
33. Herbstreit F, Peters J, Eikermann M. Increased upper airway collapsibility and blunted genioglossus muscle activity in response to negative pharyngeal pressure. Anesthesiology 2009; 110: 1253–60.
34. Caldwell JE. Clinical limitations of acetylcholinesterase antagonists. J Crit Care 2009; 24: 21–8.
35. Kirkegaard H, Heier T, Caldwell JE. Efficacy of tactile-guided reversal from cisatracurium-induced neuromuscular block. Anesthesiology 2002; 96: 45–50.
36. Paton F, Paulden M, Chambers D, et al. Sugammadex compared with neostigmine/glycopyrrolate for routine reversal of neuromuscular block: a systematic review and economic evaluation. Br J Anaesth 2010; 105: 558–67.
37. Lee C, Jahr JS, Candiotti KA, et al. reversal of profound neuromuscular block by sugammadex administered three minutes after rocuronium: a comparison with spontaneous recovery from succinylcholine. Anesthesiology 2009; 110: 1020–5.
38. Schreiber JU, Lysakowski C, Fuchs-Buder T, Tramer MR. Prevention of succinylcholine-induced fasciculation and myalgia: A meta-analysis of randomized trials. Anesthesiology 2005; 103: 877–84.
39. Bisschops MM, Holeman C, Huitink JM. Can sugammadex save a patient in a simulated ‘cannot intubate, cannot ventilate’ situation? Anesthesia 2010; 65: 936–41.
40. Vachon CA, Warner DO, Bacon DR. Succinylcholine and the open globe: tracing the teaching. Anesthesiology 2003; 99: 220–3.
41. Capron F, Fortier LP, Racine S, Donati F. Tactile fade detection with hand or wrist stimulation using train-of-four, double-burst stimulation, 50-hertz tetanus, 100-hertz tetanus, and acceleromyography. Anesth Analg 2006; 102: 1578–84.
42. Debaene B, Plaud B, Dilly MP, Donati F. Residual paralysis in the PACU after a single intubating dose of nondepolarizing muscle relaxant with an intermediate duration of action. Anesthesiology 2003; 98: 1042–8.